Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 2/20 | 0.40 |
| ▸ | AR | P10275 | 3/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | FYN | P06241 | 1/20 | 0.36 |
| ▸ | MMP2 | P08253 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MMP8 | P22894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| O-Xylene SCHEMBL3196328 | 0.89 | TSHR (0.53) | ESR2ESR1ARCXCR2CXCR1 | |
| SCHEMBL832 | 0.83 | TSHR (0.46) | ESR2CXCR2CXCR1TSHRLMNA | |
| SCHEMBL373562 | 0.79 | ESR2 (0.45) | ESR2ESR1ARCXCR2CXCR1 | |
| SCHEMBL31616078 | 0.77 | ALDH1A1 (0.36) | TSHRLMNACA1CA2ADAMTS4 | |
| SCHEMBL16955445 | 0.77 | CA2 (0.36) | TSHRLMNACA1CA2ADAMTS4 | |
| SCHEMBL3386194 | 0.76 | DYRK1A (0.47) | ESR2CXCR2CXCR1TSHRLMNA | |
| SCHEMBL491433 | 0.76 | ALDH1A1 (0.52) | ESR2ARCXCR2TSHRSOS2 | |
| SCHEMBL31609682 | 0.76 | ALDH1A1 (0.52) | ESR2ARCXCR2TSHRSOS2 | |
| SCHEMBL31032883 | 0.76 | DYRK1A (0.47) | ESR2CXCR2CXCR1TSHRLMNA | |
| SCHEMBL5756 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| CN-117736222-A | MTA synergistic PRMT5 inhibitor compounds having tricyclic or tetracyclic ring structures | 烨辉医药科技(上海)有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115279359-A | Novel thyromimetic agents | 速通医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4065098-A1 | NOVEL THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2022133037-A1 | MACROCYCLES AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2022-06-23 | — | — | WO | disclosed |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA UK LIMITED (GB) | 2022-04-28 | — | — | US | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA AB (SE) | 2020-04-09 | — | — | US | disclosed |
| EP-3621968-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | Astrazeneca AB (SE) | 2020-03-18 | — | — | EP | disclosed |
| CN-110603258-A | Heteroaryl compounds that inhibit G12C mutant RAS proteins | 阿斯利康(瑞典)有限公司 | 2019-12-20 | — | — | CN | disclosed |
| WO-2018206539-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | ASTRAZENECA AB (SE) | 2018-11-15 | — | — | WO | disclosed |
| CN-105392779-B | Tetrazolinone compound and use thereof | 住友化学株式会社 | 2018-01-19 | — | — | CN | disclosed |
| CN-105392779-A | Tetrazolinone compound and use thereof | SUMITOMO CHEMICAL CO | 2016-03-09 | — | — | CN | disclosed |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA INC. (CA) | 2012-10-25 | — | — | US | disclosed |
| EP-2491004-A2 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | Tranzyme Pharma, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| EP-2491020-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | Tranzyme Pharma, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011050270-A2 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011050276-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | TRANZYME PHARMA, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270769-A1 | METHODS OF USING MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, TMPRSS15 | ESR2 4008/4885ESR1 4117/4885AR 3857/4885 |
| US-20230048992-A1 | NOVEL THYROMIMETICS | TSHR, TPO, CHRM1 | ESR2 1837/4885ESR1 2258/4885AR 1508/4885 |
| US-20200109153-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | ESR2 2214/4885ESR1 2485/4885AR 2742/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | ESR2 1738/4885ESR1 1938/4885AR 1242/4885 |
| US-20220127281-A1 | HETEROARYL COMPOUNDS THAT INHIBIT G12C MUTANT RAS PROTEINS | KRAS, NRAS, HRAS | ESR2 2128/4885ESR1 2410/4885AR 2758/4885 |
| US-20120270807-A1 | MACROCYCLIC INHIBITORS OF SERINE PROTEASE ENZYMES | PRSS1, SPINT2, SERPINB1 | ESR2 3531/4885ESR1 3377/4885AR 3409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.